Vancouver, BC – December 6, 2017 -
Medipure Pharmaceuticals, a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced that they are further expanding both their corporate offices in Vancouver and their research labs in Burnaby, B.C., to enhance the Company’s research aimed at developing cannabinoid-derived molecules into non-addictive pharmaceutical drugs.
"These expansions come at an exciting time with more and more information coming out about the potential benefits from the various molecules within the cannabis plant," said Medipure CEO, Boris Weiss. "These expansions will allow our growing team to continue to develop benchtop research to support not only our existing pharmaceutical slate of products, but additional drugs in our drug pipeline."
The corporate offices, located in Vancouver, will add an additional 2,500 square feet, bringing the overall total to 3,800 square feet. The new space will accommodate new additions to the management and corporate team.
In addition to the corporate office expansion, the company has added 1,200 square feet to their 2,550 square foot lab facility in Burnaby, B.C., with a further 2,850 square foot expansion scheduled for the end of Q2 2018. With this expansion, the Company can further develop their molecular research and continue their delivery mechanism development, with the goal of growing the facility into a GMP site for early stage drug production. The new lab expansion will also accommodate further growth of the Medipure team as they look for qualified applicants to fill various positions, including lab technicians, management, PhD’s, and office administration.
The Company plans to add 17-19 new positions by Q2 2018.
The first stage of the Burnaby lab expansion was completed on Dec. 1, 2017, with the second stage planned to be completed by July 1, 2018. The corporate office expansion is in progress with expected completion Q1 2018.
Medipure Pharmaceuticals is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology.
Medipure Pharmaceuticals' research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well-understood by physicians, healthcare providers and prospective patients.